Cargando…
NAD(+) in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo
Mitochondria in neurons generate adenosine triphosphate (ATP) to provide the necessary energy required for constant activity. Nicotinamide adenine dinucleotide (NAD(+)) is a vital intermediate metabolite involved in cellular bioenergetics, ATP production, mitochondrial homeostasis, and adaptive stre...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369418/ https://www.ncbi.nlm.nih.gov/pubmed/34414179 http://dx.doi.org/10.3389/fcell.2021.668491 |
_version_ | 1783739288881463296 |
---|---|
author | Wang, Xinshi He, Hai-Jun Xiong, Xi Zhou, Shuoting Wang, Wen-Wen Feng, Liang Han, Ruiyu Xie, Cheng-Long |
author_facet | Wang, Xinshi He, Hai-Jun Xiong, Xi Zhou, Shuoting Wang, Wen-Wen Feng, Liang Han, Ruiyu Xie, Cheng-Long |
author_sort | Wang, Xinshi |
collection | PubMed |
description | Mitochondria in neurons generate adenosine triphosphate (ATP) to provide the necessary energy required for constant activity. Nicotinamide adenine dinucleotide (NAD(+)) is a vital intermediate metabolite involved in cellular bioenergetics, ATP production, mitochondrial homeostasis, and adaptive stress responses. Exploration of the biological functions of NAD(+) has been gaining momentum, providing many crucial insights into the pathophysiology of age-associated functional decline and diseases, such as Alzheimer’s disease (AD). Here, we systematically review the key roles of NAD(+) precursors and related metabolites in AD models and show how NAD(+) affects the pathological hallmarks of AD and the potential mechanisms of action. Advances in understanding the molecular roles of NAD(+)-based neuronal resilience will result in novel approaches for the treatment of AD and set the stage for determining whether the results of exciting preclinical trials can be translated into the clinic to improve AD patients’ phenotypes. |
format | Online Article Text |
id | pubmed-8369418 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83694182021-08-18 NAD(+) in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo Wang, Xinshi He, Hai-Jun Xiong, Xi Zhou, Shuoting Wang, Wen-Wen Feng, Liang Han, Ruiyu Xie, Cheng-Long Front Cell Dev Biol Cell and Developmental Biology Mitochondria in neurons generate adenosine triphosphate (ATP) to provide the necessary energy required for constant activity. Nicotinamide adenine dinucleotide (NAD(+)) is a vital intermediate metabolite involved in cellular bioenergetics, ATP production, mitochondrial homeostasis, and adaptive stress responses. Exploration of the biological functions of NAD(+) has been gaining momentum, providing many crucial insights into the pathophysiology of age-associated functional decline and diseases, such as Alzheimer’s disease (AD). Here, we systematically review the key roles of NAD(+) precursors and related metabolites in AD models and show how NAD(+) affects the pathological hallmarks of AD and the potential mechanisms of action. Advances in understanding the molecular roles of NAD(+)-based neuronal resilience will result in novel approaches for the treatment of AD and set the stage for determining whether the results of exciting preclinical trials can be translated into the clinic to improve AD patients’ phenotypes. Frontiers Media S.A. 2021-08-03 /pmc/articles/PMC8369418/ /pubmed/34414179 http://dx.doi.org/10.3389/fcell.2021.668491 Text en Copyright © 2021 Wang, He, Xiong, Zhou, Wang, Feng, Han and Xie. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Wang, Xinshi He, Hai-Jun Xiong, Xi Zhou, Shuoting Wang, Wen-Wen Feng, Liang Han, Ruiyu Xie, Cheng-Long NAD(+) in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo |
title | NAD(+) in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo |
title_full | NAD(+) in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo |
title_fullStr | NAD(+) in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo |
title_full_unstemmed | NAD(+) in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo |
title_short | NAD(+) in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo |
title_sort | nad(+) in alzheimer’s disease: molecular mechanisms and systematic therapeutic evidence obtained in vivo |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369418/ https://www.ncbi.nlm.nih.gov/pubmed/34414179 http://dx.doi.org/10.3389/fcell.2021.668491 |
work_keys_str_mv | AT wangxinshi nadinalzheimersdiseasemolecularmechanismsandsystematictherapeuticevidenceobtainedinvivo AT hehaijun nadinalzheimersdiseasemolecularmechanismsandsystematictherapeuticevidenceobtainedinvivo AT xiongxi nadinalzheimersdiseasemolecularmechanismsandsystematictherapeuticevidenceobtainedinvivo AT zhoushuoting nadinalzheimersdiseasemolecularmechanismsandsystematictherapeuticevidenceobtainedinvivo AT wangwenwen nadinalzheimersdiseasemolecularmechanismsandsystematictherapeuticevidenceobtainedinvivo AT fengliang nadinalzheimersdiseasemolecularmechanismsandsystematictherapeuticevidenceobtainedinvivo AT hanruiyu nadinalzheimersdiseasemolecularmechanismsandsystematictherapeuticevidenceobtainedinvivo AT xiechenglong nadinalzheimersdiseasemolecularmechanismsandsystematictherapeuticevidenceobtainedinvivo |